Browsing by Author "Gcelu, Ayanda"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Open Access
    A retrospective study of patients with biologics treatment at Groote Schuur and Red Cross Children's War Memorial Hospitals
    (2020) Ahmed, Mohammed Awad Eltoum; Hodkinson, Bridget; Gcelu, Ayanda
    Introduction. The high cost and concern of adverse events, particularly infections, limit the use of biologic disease-modifying anti-rheumatic (bDMARD) therapies. We undertook this retrospective study to document their use for immune-mediated diseases (IMDs) and explore the efficacy, safety, adherence and screening practices prior to initiating bDMARDs in a tertiary referral hospital. Methods. A folder review of all adult and paediatric patients treated for IMDs with bDMARDs at Groote Schuur and Red Cross Hospitals between January 2013 and December 2019. Clinico-demographic particulars, details of bDMARD therapy, and adverse events were collated. Changes in disease activity were measured by diseasespecific tools at 6, 12, 24-months and at the last available visit, and patient adherence to bDMARDs was explored by folder and pharmacy record review. Results. We studied 151 folders, with 182 bDMARDs uses (29 patients used more than 1 bDMARD). Patients were from rheumatology (n= 38: 13 rheumatoid arthritis; 10 spondyloarthritis, 5 Systemic Lupus Erythematosus (SLE) , 5 inflammatory myositis and 5 other conditions); gastroenterology (n=31; 26 Crohn`s and 5 Ulcerative Colitis), dermatology (n=9; psoriasis), neurology (n=4, ophthalmology (n= 25; 6 scleritis, 18 uveitis, 1 optic neuritis), and paediatrics (n= 45, 26 juvenile idiopathic arthritis , 12 SLE, 7 other conditions). The bDMARDs used were TNF inhibitors (112), rituximab (55), tocilizumab (10), anakinra (3), abatacept (1), and tofacitinib (1). The vast majority of patients had an excellent response and were in low disease activity or remission at their last available visit. Adverse events included severe infection (4), tuberculosis (TB) (2), mild infection (4), severe allergic reaction (3), mild skin reaction (14), elevated liver enzymes (2), and worsening interstitial lung disease ILD (1). bDMARD Therapy was discontinued in 18 patients, most commonly due to adverse reaction (9), lack of response (3), poor adherence (2), or remission (1). bDMARD Therapy was changed to alternative therapy in 29 patients, most commonly because of poor response (14), or adverse effects (9) or poor adherence (3). Poor adherence or patients lost to follow-up was noted in 18/182 (9.9%). Complete latent TB infection screening with chest x-ray and TB skin test was performed in only 55 (36.4 %) but INH prophylaxis was given to 51/88 (57.9%) of patients prescribed TNFi therapy. Hepatitis B screening performed in 93 (61.6 %) patients, but most patients (72.2 %) were not tested for Hepatitis B core ab. Hepatitis C screening was performed in 81 (53.6 %) patients. Only 88 (58.3%) patients had a recent HIV test. The majority (17.2%) received the influenza vaccine, but only 24 (15.8 %) received pneumococcal vaccination. Discussion and Conclusion. bDMARD therapy was an effective treatment, and the most common adverse effect was infection (7.2%), with 2 TB infections. Vaccination and screening for TB, viral hepatitis and HIV was suboptimal. Of concern, poor adherence to bDMARDs was frequently encountered.
  • Thumbnail Image
    Item
    Open Access
    Does alopecia have diagnostic weight in systemic lupus erythematosus?
    (2022) Knight, Lauren Kerry; Jessop, Susan; Gcelu, Ayanda
    Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder characterised by autoantibody production and a wide spectrum of clinical manifestations. Non-scarring alopecia (hair loss) is reported to occur in up to 80% of individuals with SLE, occurring primarily in the active phase. Alopecia is also reported in up to a third of the general population, begging the question of how much diagnostic weight alopecia really has in SLE. METHODS We conducted a cross-sectional cohort study of patients with confirmed SLE, by the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria, managed at the Lupus clinic at Groote Schuur Hospital, a tertiary referral hospital in Cape Town, South Africa. Age, sex and race matched controls were recruited from the Dermatology clinic at the same hospital. Participants were questioned about alopecia (‘self-reported') and examined for alopecia clinically and dermoscopically (‘confirmed alopecia'). Alopecia was classified according to the likely cause and evaluated as to whether or not it was related to SLE and to disease activity. RESULTS The study included 90 participants with SLE and 90 controls. Females predominated in the study population, with a mean age of 37.13 (range 18-69) for cases and 37.62 (range 18-72) in controls. Demographics of the 2 groups were equally matched, with two thirds (64.4%) of cases and controls self- identified as being mixed race, 33.3% as black african and 2.3% as white. Alopecia (self-reported and confirmed) was found equally in cases and control groups. In a third of the people with SLE (34, 38%) alopecia was recorded by the clinician as one of the classification criteria used by the clinician in recording the diagnosis of SLE. In 7/34 (21%) of these patients, the classification of SLE would not have been made by criteria in the absence of alopecia. Forty patients were found to have clinically apparent alopecia, 7 of these (17.5%) having diffuse alopecia. Of the remaining 33 patients with alopecia, androgenic alopecia (12/33) was the commonest form. Likewise, androgenic alopecia was the commonest type of confirmed alopecia in controls (11/33, 33.3%). Patients with self-reported alopecia had significantly higher Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores than people without hair loss. However, there was no statistically significant difference in SLEDAI scores between those with clinically confirmed alopecia and those with self-reported alopecia (n = 40, M = 2.88, SD = 3.35 vs n = 50, M = 2.56, SD = 3.37; t = 0.44, p = 0.660, d = 0.09). CONCLUSION Within our population the incidence of alopecia was the same in people with SLE and in controls. Hair loss was identified as androgenic alopecia in the majority of affected cases and controls. This lack of difference in type of alopecia among participants highlights the low specificity of non-scarring alopecia as a criterion for SLE and further supports the weighting of classification criteria within the various domains in the EULAR/ACR criteria.